KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. - Wikidata - wikimedia - TriplyDB

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

http://www.wikidata.org/entity/Q27851422

about

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic Markers of resistance to anti-EGFR therapy in colorectal cancer Molecular origins of cancer: Molecular basis of colorectal cancer Current targeted therapies in the treatment of advanced colorectal cancer: a review Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances Impact of somatic mutations on patterns of metastasis in colorectal cancer Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer Molecular phenotypes of colorectal cancer and potential clinical applications Precision medicine in colorectal cancer: the molecular profile alters treatment strategies K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value Recent applications of chemosensitivity tests for colorectal cancer treatment EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)Colorectal Cancer Biomarkers: Where Are We Now?CIViC database In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer Quantitative and sensitive detection of rare mutations using droplet-based microfluidics Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter Data for cancer comparative effectiveness research: past, present, and future potential.

P2860

ce3201f9d98d29add209ee487a6bf2056a00720c ee2e9beb744314684bdd4c294889627d8880f21d

P248

Q21128654-AFC98DE8-15C3-4552-88FE-EBE7C86F8DD3 Q24598640-AB22B763-50F9-47A8-80A1-CE508CCD4669 Q24617331-CE5F1EED-9792-48B6-A5E6-980FD36AD813 Q26740067-AEAC4668-9929-4A1E-92AC-EFCB667543A5 Q26748924-E18C76FE-E111-48DE-BBAB-BEB78EED1B8D Q26751344-BDF633D2-F932-4F92-B0C7-F8A2628D8A3A Q26766535-799244F7-D918-478D-B4DD-AE3DB4503078 Q26768427-50D8FC73-7B74-436B-AD07-A560201822D4 Q26772279-6B197AB5-6E8B-43F0-A7EE-D2D17AE079C6 Q26777108-0280ED5F-12C6-41A6-82D1-F25032F6F558 Q26785725-A79B7B15-7971-4F67-BD67-B35B0DB81099 Q26795558-0F2B751E-275E-4210-8D96-EBC437D007A5 Q26829425-86C4E9BE-8603-42E4-B10A-DB28089EF675 Q26851075-1BBDC8C5-556E-482F-88BB-D987548B9219 Q26865056-697A29D8-7C1F-4BC2-9128-DCD635118ECA Q26865436-BE8D1304-DB67-47FB-926E-6C1108E11CD7 Q26992267-D372198F-225F-4735-B530-2EDB3ECCAA8E Q27002155-E6E1F9E6-B5D6-4544-BA15-FA99AAFAD2A5 Q27003134-EB716C43-5B89-4690-8B83-825E5E2ABA3D Q27612411-C3D4F796-AF37-4C7A-AA1D-9D05EA58F6ED Q27684047-B7A700B5-0178-4823-A037-AEECEA3BB625 Q27693248-9C03BED9-0E4C-48CB-8B42-4F3661A8E22C Q27851532-8B6247C9-AE65-4644-92CB-60EFBC39938F Q27851586-80D372B5-7F06-413D-97FB-685AD3C98921 Q27851658-99DB9D7C-5230-4DEB-8690-6E7F3D6CB192 Q27851674-E0C6AF27-9640-4443-8B16-624082BE69B5 Q27852105-D216243C-1B60-421E-A4AB-653F88950D56 Q28084216-CE52C2A2-D6C8-49D1-ABE2-EA0CA4B97221 Q28238121-F1670D31-952F-4000-BC40-12B718D0821E Q28257098-98B1ED08-4CBE-4876-82BF-4BCCB4556D52 Q28287088-8A034A09-DF09-4D7D-BA4A-823DD8DE2751 Q28468648-85CE5926-A57F-4E1D-8C0D-8C9BE7ADF824 Q28476652-D9275F0E-2582-4DEC-886F-232C490E185E Q28484970-5CE2E16A-90B6-4740-8D9E-E51E31139F0A Q28488319-D37092F2-9824-4A53-B0F7-E232EE9D2136 Q28534874-E3D65B40-4226-4202-AEEF-5F1B3C3C1A06 Q28543278-8B7072FF-1552-4853-A935-461C9F6447D3 Q30235144-3CF126BC-68E7-4365-8DEF-B56FCAECEC8F Q30276647-8B70A239-5450-4BDA-A45D-3F360363DA42 Q30416509-BC4E112A-95D5-4D20-98A7-086C0CDB8B11

P2860

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

http://www.wikidata.org/entity/Q27851422

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

KRAS mutations as an independe ...... cancer treated with cetuximab.

@ast

KRAS mutations as an independe ...... cancer treated with cetuximab.

@en

KRAS mutations as an independe ...... cancer treated with cetuximab.

@nl

type

label

KRAS mutations as an independe ...... cancer treated with cetuximab.

@ast

KRAS mutations as an independe ...... cancer treated with cetuximab.

@en

KRAS mutations as an independe ...... cancer treated with cetuximab.

@nl

prefLabel

KRAS mutations as an independe ...... cancer treated with cetuximab.

@ast

KRAS mutations as an independe ...... cancer treated with cetuximab.

@en

KRAS mutations as an independe ...... cancer treated with cetuximab.

@nl

P1433

Q27851422-3681596F-8AA6-4CB8-A4A0-220D67D451AD

P1476

Q27851422-E0EE0CD7-9D93-44BF-B329-F07B9B663846

P2093

Q27851422-2625DF60-302D-4C2A-A529-C422480DA4CF

Q27851422-3F1B1663-07EE-4170-9453-F130537731D5

Q27851422-5FCB835D-723C-432E-80BD-6EF07EA2374A

Q27851422-79CF4D71-407F-40E4-9C19-72B62F143337

Q27851422-985CED3F-49BB-4F07-96E6-359254BC59F2

Q27851422-AD56D2BA-37FA-4EBF-A567-AF43D9616B96

Q27851422-AE0BED08-AE43-4854-8ED4-D5EE31BEBA8D

Q27851422-B2B3E103-CA9F-4945-B2E4-85A465BA742A

Q27851422-B35FAAA2-5011-4C51-8110-984536E6870F

Q27851422-B627623F-619F-47B8-ADD7-45517D57F739

P304

Q27851422-559AB0C4-2208-43BF-849C-09A0A97A9657

P31

Q27851422-8DB29050-7DD0-4DF0-8BD0-64E957DA401D

P3181

Q27851422-4626C6A0-4B6E-4424-9792-B030EEA5011C

P356

Q27851422-F8943F92-05FE-4857-8E46-5701894D0091

P407

Q27851422-40B464C8-33A4-41AB-A14C-E5D8F3D94F2D

P433

Q27851422-B26AFF70-A494-4595-9F3E-840EB38CE99D

P478

Q27851422-2E6091F2-BE8E-4950-A8DA-7206751E7169

P50

Q27851422-752CA046-933F-480F-AB77-1786867BC8E0

Q27851422-92B116E6-A682-470A-932D-4EC52880F91C

Q27851422-9B363A42-CDE6-463F-B8C3-7CFE21EF1D64

Q27851422-A30A32E5-120C-434A-9732-7BF37CEC9211

Q27851422-B0B4D134-4305-40F6-8448-517E066D200E

Q27851422-D207503E-6599-4F5C-BD21-8CDBA43DBD67

P577

Q27851422-1B12D631-A851-4F5C-938C-EA8ED7CC4A55

P698

Q27851422-74F4BA03-709D-454E-8898-1884D28787E4

P921

Q27851422-9220D486-4D63-4BB6-8949-C6222F4D0120

Q27851422-D981A827-4CD3-4BF0-8559-6B4973AC508E

P3181

P356

JCO.2007.12.5906

P1433

Journal of Clinical Oncology

P1476

KRAS mutations as an independe ...... cancer treated with cetuximab

@en

P2093

Astrid Lièvre

http://www.w3.org/2001/XMLSchema#string

Bruno Landi

http://www.w3.org/2001/XMLSchema#string

Christophe Louvet

http://www.w3.org/2001/XMLSchema#string

Delphine Le Corre

http://www.w3.org/2001/XMLSchema#string

Emmanuel Buc

http://www.w3.org/2001/XMLSchema#string

Fréderic Bibeau

http://www.w3.org/2001/XMLSchema#string

Frédérique Penault-Llorca

http://www.w3.org/2001/XMLSchema#string

Gorana Tomasic

http://www.w3.org/2001/XMLSchema#string

Jean-François Emile

http://www.w3.org/2001/XMLSchema#string

Marie-Danièle Diebold

http://www.w3.org/2001/XMLSchema#string

P304

374-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1764367

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2007.12.5906

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Laurent-Puig

Jean-Baptiste Bachet

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18202412

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer